Compare BridgeBio Pharma Inc (BBIO) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Prudential Financial Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Prudential Financial Inc trades at $122.19 (market cap $42.13B). The key difference: Prudential Financial Inc is far larger — about 2.5× BridgeBio Pharma Inc's market cap, and Prudential Financial Inc pays a 4.59% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | PRU | |
|---|---|---|
Market Cap | $16.61B | $42.13B |
Sector | Health | Financials |
52-Week High | $90.17 | $123.93 |
52-Week Low | $47.29 | $92.00 |
Enterprise Value | $18.16B | $70.91B |
Dividend Yield | — | 4.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Prudential Financial (PRU) trades at $121.28, down 0.18% today, with a bullish technical signal from moving averages and ADX indicators. The stock shows strong fundamentals with a P/E of 11 and net income margin of 6.04%, supported by Q2 2026 earnings beating estimates. Recent news highlights strategic refocusing and institutional buying interest, though China tax concerns caused temporary volatility.
Outlook remains positive due to earnings beats and capital-light strategy, but risks include interest rate sensitivity and geopolitical exposure. Analyst consensus is cautious with a $110 price target below current levels, suggesting limited upside despite solid operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
